Latha Thanneer, MD
Cardiovascular Disease · White Plains, NYNPI 1306927579
Payments from drug & device makers
Across 75 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$498
- Merck$216
- AstraZeneca$76
- Boehringer Ingelheim$66
- Kowa Pharmaceuticals America, Inc.$55
- Avanir Pharmaceuticals, Inc.$49
- plus $526 from 19 others
What the payments were for
- Food & beverage$1,46499%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 28 | $498 |
| Merck | 11 | $216 |
| AstraZeneca | 4 | $76 |
| Boehringer Ingelheim | 3 | $66 |
| Kowa Pharmaceuticals America, Inc. | 4 | $55 |
| Avanir Pharmaceuticals, Inc. | 2 | $49 |
| Amgen | 2 | $49 |
| Lundbeck LLC | 2 | $47 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Irhythm Technologies, Inc. | 1 | $35 |
| Alnylam Pharmaceuticals Inc. | 1 | $33 |
| Almatica Pharma LLC | 1 | $31 |
| Bayer | 1 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Exact Sciences | 1 | $29 |
| Abiomed | 1 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Lilly USA, LLC | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $21 |
| GSK | 1 | $20 |
| Pulmonx Corporation | 1 | $20 |
| Mylan Specialty L.p. | 1 | $19 |
| Sanofi | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
How this compares
$1,486 in reported general payments places this provider in the 45th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 26 | $31,859 |
| Ranolazine ErRanolazine | 12 | $1,393 |
| Metoprolol Succinate | 88 | $1,370 |
| Metoprolol Tartrate | 47 | $276 |
| Carvedilol | 18 | $269 |
| Amlodipine Besylate | 54 | $256 |
| Atorvastatin Calcium | 30 | $251 |
| Rosuvastatin Calcium | 23 | $143 |
| Hydralazine Hcl | 12 | $82 |
| Lisinopril | 17 | $34 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in White Plains
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
- Szilard VorosStony Brook$3.7M
- Valentin FusterNew York$2.9M
- Sean DonahoeRiverhead$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.